BioSpace News Archive

Thanks to a rough launch of its Biogen-partnered Alzheimer’s disease treatment, Eisai will likely miss its target of treating 10,000 patients with Leqembi by the end of March 2024.

While analysts are bullish on Novo Holdings’ $16.5 billion acquisition of Catalent, they say it raises questions for companies that have contracted the CDMO for manufacturing.

This week Lori, Greg and Tyler discuss ⁠drug pricing reforms⁠. CMS sent offers to manufacturers of the 10 drugs that have been selected for Medicare price negotiations. What’s the best way forward that benefits patients while still supporting the innovation that makes these drugs possible? How will the election impact negotia

Hit with lower sales of its COVID-19 antiviral Veklury and the weak performance of its HIV franchise, Gilead Sciences reported a 4% year-over-year revenue loss in the fourth quarter of 2023.

Venture capital firm Scion Life Sciences, led by investors Samuel Hall, Aaron Kantoff and Tadd Wessel, seeks to establish biotechs through to maturity as late- or commercial-stage companies.

Takeda, AbbVie and Moderna are among the companies with open positions.

Eli Lilly on Tuesday said it is already making manufacturing investments for orforglipron, its next-generation oral weight-loss candidate that recently moved into Phase III development.

Jazz Pharmaceuticals is acquiring Redx Pharma’s KRAS inhibitor program including preclinical-stage drug candidates, with the companies working to advance assets through IND-enabling studies.

A proposed class-action lawsuit accuses Johnson & Johnson of failing to negotiate fair prescription drug prices for its employees, but experts note that the company is also on the hook for benefits costs.

Moberg Pharma ABs marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter pharmaceuticals - has now launched sales of MOB-015 under the Terclara® brand.